Abstract
Inactivation of Dickkopf-3 (DKK3) is closely associated with a poor prognosis in various solid tumor and hematologic malignancies. Promoter hypermethylation is one potential cause of DKK3 inactivation. However, whether other mechanisms lead to DKK3 inactivation and the subsequent effects of these inactivations on cell proliferation and the Wnt signaling pathway in adult B acute lymphoblastic leukemia (B-ALL) remain unclear. In the present study, we found that low DKK3 expression levels were associated with high miR-708 expression and promoter hypermethylation in adult B-ALL. miR-708 was confirmed to directly decrease DKK3 expression in Nalm-6 and BALL-1 cells. Additionally, a miR-708 inhibitor decreased cell proliferation mainly through apoptosis and cell cycle arrest at the G1 phase, and these effects were eliminated by DKK3 siRNA treatment. Moreover, the demethylating agent 5-aza-2′-deoxycytidine (5-aza) decreased the methylation state of the DKK3 promoter based on methylation-specific PCR (MSP) and bisulfite genomic sequencing PCR (BSP), although this demethylation effect was not enhanced by the miR-708 inhibitor. The miR-708 inhibitor or 5-aza significantly increased DKK3 expression and decreased p-GSK3β, cyclin D1 and nuclear and cytoplasmic β-catenin protein expression, indicating that the Wnt/β-catenin signaling pathway was inhibited. These effects became more pronounced when the miR-708 inhibitor and 5-aza were used simultaneously. These findings provide greater insights into the mechanisms that increase DKK3 expression and suggest that a miR-708 inhibitor and 5-aza might be useful as targeted therapies for adult B-ALL.
Highlights
Adult B acute lymphoblastic leukemia (B-ALL) has a poor prognosis, with a 5-year overall survival of approximately 35% [1]
The demethylating agent 5-aza-2’deoxycytidine (5-aza) decreased the methylation state of the DKK3 promoter based on methylation-specific PCR (MSP) and bisulfite genomic sequencing PCR (BSP), this demethylation effect was not enhanced by the miR-708 inhibitor
Decreased DKK3 expression is related to a poor prognosis in patients with ALL [11]
Summary
Adult B acute lymphoblastic leukemia (B-ALL) has a poor prognosis, with a 5-year overall survival of approximately 35% [1]. The silencing of Wnt antagonist genes is associated with activation of the Wnt signaling pathway and is regarded as an independent poor prognostic factor for patients with acute myelocytic leukemia (AML) [6]. As an antagonist of the Wnt signaling pathway, decreased DKK3 expression is related to dismal prognoses in breast cancer, renal cell carcinoma and ALL patients [7,8,9,10,11]. Down-regulation or silencing of DKK3 is associated with promoter CpG methylation in chronic lymphocytic leukemia, myelodysplastic syndrome, AML and ALL [9,10,11,12,13,14]. The regulation and biological functions of DKK3 in adult B-ALL remain unclear
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.